StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
SNDXBullishEarningsnews
High materiality8/10

Syndax posts strong 3Q26 revenue growth; revumenib and axatilimab momentum

Nov 2, 2026, 7:05 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong YoY revenue growth, product leadership in R/R NPM1m and KMT2Ar, and a concrete 4Q26 data catalyst suggest potential multiple expansion; risk remains from execution/news cadence and competitive dynamics.

AI summary

What happened, with direct paths to the underlying reporting

Syndax posted 3Q26 revenue of $83.3M, driven by Revuforj and Niktimvo growth. Revumenib revenue rose 90% YoY to $60.7M, with 4Q26 data planned across multiple genetic subtypes; management cites real-world studies as potential catalysts. A conference call is scheduled today at 4:30 p.m. ET to discuss results.

  • Total revenue $83.3M in 3Q26, up 82% YoY.
  • Revuforj net revenue $60.7M in 3Q26, up 90% YoY.
  • Niktimvo net revenue $67.4M in 3Q26; collaboration revenue $22.6M.
  • New revumenib data expected in 4Q26 across multiple leukemia subtypes.
  • Conference call today at 4:30 p.m. ET.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event